Literature DB >> 12876900

Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines.

S Blower1, E J Schwartz, J Mills.   

Abstract

Mathematical models can be used as health policy tools and predictive tools. Here we review how mathematical models have been used both to predict the consequences of specific epidemic control strategies and to design epidemic control strategies. We review how models have been used to evaluate the potential impact on HIV epidemics of (i) combination antiretroviral therapies (ART) and (ii) imperfect vaccines. In particular, we discuss how models have been used to predict the potential effect of ART on incidence rates, and to predict the evolution of an epidemic of drug-resistant HIV. We also discuss, in detail, how mathematical models have been used to evaluate the potential impact of prophylactic, live-attenuated and therapeutic HIV vaccines. We show how HIV vaccine models can be used to evaluate the epidemic-level impact of vaccine efficacy, waning in vaccine-induced immunity, vaccination coverage level, and changes (increases or decreases) in risky behavior. We also discuss how mathematical models can be used to determine the levels of cross-immunity that vaccines will need to attain if they are to be used to control HIV epidemics in countries where more than one subtype is being transmitted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12876900

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  21 in total

1.  Systematic evaluation of the population-level effects of alternative treatment strategies on the basic reproduction number.

Authors:  Dmitry Gromov; Ingo Bulla; Ethan O Romero-Severson
Journal:  J Theor Biol       Date:  2018-11-27       Impact factor: 2.691

2.  Racial/ethnic and age disparities in HIV prevalence and disease progression among men who have sex with men in the United States.

Authors:  H Irene Hall; Robert H Byers; Qiang Ling; Lorena Espinoza
Journal:  Am J Public Health       Date:  2007-04-26       Impact factor: 9.308

3.  What can HIV vaccine trials teach us about future HIV vaccine dissemination?

Authors:  Peter A Newman; Naihua Duan; Lisa Kakinami; Kathleen Roberts
Journal:  Vaccine       Date:  2008-03-28       Impact factor: 3.641

Review 4.  Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities.

Authors:  Lisa Maher; Bethany White; Margaret Hellard; Annie Madden; Maria Prins; Thomas Kerr; Kimberly Page
Journal:  Vaccine       Date:  2010-09-09       Impact factor: 3.641

5.  Relationship-level analysis of drug users' anticipated changes in risk behavior following HIV vaccination.

Authors:  April M Young; Daniel S Halgin; Jennifer R Havens
Journal:  AIDS Care       Date:  2015-03-02

6.  Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting?

Authors:  H M Truong; H-H M Truong; T Kellogg; J D Klausner; M H Katz; J Dilley; K Knapper; S Chen; R Prabhu; R M Grant; B Louie; W McFarland
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

7.  Beating the placebo in HIV prevention efficacy trials: the role of the minimal efficacy bound.

Authors:  Dobromir T Dimitrov; Benoît R Mâsse; Marie-Claude Boily
Journal:  J Acquir Immune Defic Syndr       Date:  2013-01-01       Impact factor: 3.731

8.  Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES).

Authors:  Peter A Newman; Sung-Jae Lee; Naihua Duan; Ellen Rudy; Terry K Nakazono; John Boscardin; Lisa Kakinami; Steven Shoptaw; Allison Diamant; William E Cunningham
Journal:  Health Serv Res       Date:  2009-09-24       Impact factor: 3.402

9.  Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example.

Authors:  Kyeen M Andersson; Douglas K Owens; Eftyhia Vardas; Glenda E Gray; James A McIntyre; A David Paltiel
Journal:  J Acquir Immune Defic Syndr       Date:  2007-09-01       Impact factor: 3.731

Review 10.  Modelling sexual transmission of HIV: testing the assumptions, validating the predictions.

Authors:  Rebecca F Baggaley; Christophe Fraser
Journal:  Curr Opin HIV AIDS       Date:  2010-07       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.